Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Crystallin beta B1 is a structural protein that represents one of the primary components of the vertebrate eye lens, encoded by the CRYBB1 gene. It belongs to the beta-crystallin family, which forms oligomeric complexes essential for lens transparency and refractive function. Beta B1 crystallin is especially notable for its role in forming higher-order protein assemblies through homo- and hetero-oligomerization with other beta-crystallins. The protein undergoes age-related and maturation-related truncations, and mutations or misfolding can lead to the formation of protein aggregates and cataracts, which are a major cause of reduced vision. Unlike receptor or enzyme targets, crystallin beta B1 is not an active molecule in signaling or metabolism, but changes in its structural integrity have direct clinical consequences for lens health. There are currently no known drugs that act directly upon it.
Not applicable. Since there are no drugs that modulate Crystallin beta B1 directly, mechanism of action is not defined
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Crystallin beta B1 (CRYBB1).